The human 20S Immunoproteasome is able to degrade substrates in an ATP-independent manner in vitro. It can be activated chemically with SDS (0.035%) or by the addition of PA28. Reaction conditions will need to be optimized for each specific application. We recommend an initial i20S Proteasome concentration of 0.5-5 nM.
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins.Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration.The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard.In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Formulation | X mg/ml (X μM) in 50 mM HEPES pH 7.6, 100 mM NaCl, 1 mM DTT |
Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
The 20S Immunoproteasome is a modified form of the constitutively active 20S Proteasome core particle and is the catalytic subunit of the multicomplex Immunoproteasome. The structure of the 20S Immunoproteasome is similar to the 20S Proteasome, which is composed of 28 nonidentical subunits arranged into four stacked rings. However, during 20S Immunoproteasome assembly, the three catalytic beta subunits,beta 1,beta 2, andbeta 5, in the two interior rings of the 20S Proteasome are replaced by three IFN gamma -inducible catalytic subunits:beta 1i/LMP2,beta 2i/MECl1, andbeta 5i/LMP7. The 20S Immunoproteasome is commonly associated with the 19S, PA28 alpha / beta, or the PA28 gammaregulatory complexes. 20S Immunoproteasome expression is enriched in antigen presenting cells of the immune system where the 20S Immunoproteasome selectively degrades intracellular proteins in a manner that optimizes the generation of peptides for MHC class I antigen presentation. Selective inhibition of 20S Immunoproteasome proteolytic activity using small molecule inhibitors is being examined for therapeutic intervention in cancer and inflammatory diseases. This protein complex has been purified from Burkitt"s lymphoma cells (Ramos, RA1, CRL-1596) following stimulation with IFN-gammaand IL-2.
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsThere are currently no reviews for this product. Be the first toreview Human Ramos Cell 20S Immunoproteasome Protein, CF and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Boston Biochem是泛素相关研究产品的全球领先生产商。自1997年以来,我们的使命一直是为泛素蛋白酶体途径(UPP)研究人员提供创新工具,以促进并加速药物发现的努力。波士顿生物化学专门从事泛素和类泛素(UBL)蛋白(例如Apg8,FAT10,ISG15,NEDD8,SUMO,UFM1)以及相关酶,底物,抑制剂和试剂盒的几种相关产品系列。